Pharmaceutical Montelukast Sodium Powder Montelukast Sodium

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Montelukast sodium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Montelukast Sodium
• Name: Montelukast Sodium Powder
• Assay: HPLC 99%
• Appearance: White Powder
• Color: White
• CAS No.: 151767-02-1
• Mf: C35h35clnnao3s
• MW: 558.64
• Melting Point: 84.90
• Boiling Point: 750.5
• Density: 1.272
• Test Method: HPLC
• Grade: Pharmaceutical Grade
• Application: Pharmaceutical
• Specific: COA
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Montelukast sodium Powder Montelukast sodium

Product Description

Product Details

Product Name	Montelukast Sodium
Appearance	White Powder
CAS No.	151767-02-1
MF	C35h35clnnao3s
MW	558.64

Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific mechanism of action, it does not interact with other asthma medications such as theophylline.Another leukotriene receptor antagonist is zafirlukast (Accolate)

Application&Function

Montelukast is a potent oral formulation that can significantly improve asthma inflammation indicators and belongs to the leukotriene receptor antagonist. Leukotriene is a chemical substance released in the body during inflammatory stimulation (such as inhalation of allergens). Montelukast works by inhibiting leukotrienes in the body and has high affinity and selectivity for type I cysteinyl leukotriene receptors. It can effectively inhibit the physiological effects of the potent inflammatory mediator cysteinyl leukotriene (LTC4, LTD4, LTE4) binding to type I cysteinyl leukotriene (CysLT1) receptors without any receptor agonist activity. Currently used clinically for the prevention and long-term treatment of asthma in adults aged 15 and above, including the prevention of daytime and nighttime asthma symptoms, treatment of aspirin sensitive asthma patients, and prevention of exercise-induced bronchoconstriction; In addition, Montelukast is also used to alleviate symptoms caused by seasonal allergic rhinitis (sneezing, nasal congestion, runny nose, and nasal itching).

Specification